BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12865786)

  • 1. Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model.
    Hirshberg B; Preston EH; Xu H; Tal MG; Neeman Z; Bunnell D; Soleimanpour S; Hale DA; Kirk AD; Harlan DM
    Transplantation; 2003 Jul; 76(1):55-60. PubMed ID: 12865786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppression With CD40 Costimulatory Blockade Plus Rapamycin for Simultaneous Islet-Kidney Transplantation in Nonhuman Primates.
    Oura T; Hotta K; Lei J; Markmann J; Rosales I; Dehnadi A; Kawai K; Ndishabandi D; Smith RN; Cosimi AB; Kawai T
    Am J Transplant; 2017 Mar; 17(3):646-656. PubMed ID: 27501203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720.
    Wijkstrom M; Kenyon NS; Kirchhof N; Kenyon NM; Mullon C; Lake P; Cottens S; Ricordi C; Hering BJ
    Transplantation; 2004 Mar; 77(6):827-35. PubMed ID: 15077021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SV40 infection associated with rituximab treatment after kidney transplantation in nonhuman primates.
    Maki T; Carville A; Stillman IE; Sato K; Kodaka T; Minamimura K; Ogawa N; Kanamoto A; Gottschalk R; Monaco AP; Marr-Belvin A; Westmoreland SV; Sehgal P
    Transplantation; 2008 Mar; 85(6):893-902. PubMed ID: 18360273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report.
    Stevens RB; Mercer DF; Grant WJ; Freifeld AG; Lane JT; Groggel GC; Rigley TH; Nielsen KJ; Henning ME; Skorupa JY; Skorupa AJ; Christensen KA; Sandoz JP; Kellogg AM; Langnas AN; Wrenshall LE
    Transplantation; 2008 May; 85(10):1391-9. PubMed ID: 18497677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modern approaches to combining sirolimus with calcineurin inhibitors.
    Stevens RB
    Transplant Proc; 2008 Dec; 40(10 Suppl):S21-4. PubMed ID: 19100901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation.
    Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
    Transplant Proc; 2005 Mar; 37(2):1326-7. PubMed ID: 15848711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?
    Desai NM; Goss JA; Deng S; Wolf BA; Markmann E; Palanjian M; Shock AP; Feliciano S; Brunicardi FC; Barker CF; Naji A; Markmann JF
    Transplantation; 2003 Dec; 76(11):1623-5. PubMed ID: 14702535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parameters favouring successful adult pig islet isolations for xenotransplantation in pig-to-primate models.
    Dufrane D; D'hoore W; Goebbels RM; Saliez A; Guiot Y; Gianello P
    Xenotransplantation; 2006 May; 13(3):204-14. PubMed ID: 16756563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation.
    Pan H; Lu HM; Hu WM; Tian BL; Liu XB; Zhang ZD; Mai G
    Transplant Proc; 2007 Dec; 39(10):3452-4. PubMed ID: 18089405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
    Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
    Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model.
    Berman DM; Cabrera O; Kenyon NM; Miller J; Tam SH; Khandekar VS; Picha KM; Soderman AR; Jordan RE; Bugelski PJ; Horninger D; Lark M; Davis JE; Alejandro R; Berggren PO; Zimmerman M; O'Neil JJ; Ricordi C; Kenyon NS
    Transplantation; 2007 Aug; 84(3):308-15. PubMed ID: 17700154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody.
    Molano RD; Pileggi A; Berney T; Poggioli R; Zahr E; Oliver R; Malek TR; Ricordi C; Inverardi L
    Transplantation; 2003 Jun; 75(11):1812-9. PubMed ID: 12811239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up.
    Mangus RS; Fridell JA; Vianna RM; Kwo PY; Chen J; Tector AJ
    Liver Transpl; 2012 Jul; 18(7):786-95. PubMed ID: 22237953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppression for pancreatic islet transplantation.
    Berney T; Buhler LH; Majno P; Mentha G; Morel P
    Transplant Proc; 2004 Mar; 36(2 Suppl):362S-366S. PubMed ID: 15041369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of intra-islet endothelial cells in islet allo-immunity.
    Bharat A; Saini D; Benshoff N; Goodman J; Desai NM; Chapman WC; Mohanakumar T
    Transplantation; 2007 Nov; 84(10):1316-23. PubMed ID: 18049117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of hepatocyte-rich liver cell mixture and liver fibroblasts on prolonging graft islet survival in rats without immunosuppressive drugs.
    Soto-Montenegro L; Zugasti-Murillo A; Rollán E; Alvarez Y; Alvarez G; Jara-Albarrán A
    Exp Clin Endocrinol Diabetes; 2004 Nov; 112(10):580-6. PubMed ID: 15578333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permanent acceptance of mitomycin C-treated islet allograft.
    Matsuyama S; Gunji T; Ise K; Sato Y; Saito T; Gotoh M
    Transplantation; 2003 Jul; 76(1):65-71. PubMed ID: 12865788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.